To assess the cost-effectiveness of pembrolizumab compared with ipilimumab in patients with unresectable or metastatic melanoma (advanced melanoma) previously untreated with ipilimumab, from the perspective of a Canadian publicly funded healthcare system.
Results
Pembrolizumab is projected to increase the life expectancy of patients by 1.36 years, which corresponds to a gain of 1.1 QALYs over ipilimumab over a 20-year time horizon. In the base-case analysis, the incremental cost per QALY gained with pembrolizumab vs ipilimumab (discounted) is $52,829/QALY. Results of one-way and probabilistic sensitivity analyses show that the results are cost-effective in most scenarios.
Conclusions
Pembrolizumab improves QALYs and is a cost-effective therapeutic option compared to ipilimumab in advanced melanoma patients.
• PFS: a piecewise modeling approach was used -KN006 Kaplan-Meier (KM) estimates were used until Week 13 at which point all patients should have received their first scan -The best-fitting parametric function was used for each drug (log-normal for IPI, and Weibull for pembrolizumab) from Week 13 onwards
• Long-term survival data suggest that a proportion of cancer patients treated by modern immunotherapies, such as pembrolizumab, can achieve long-term survival, which cannot be captured by conventional statistical parametric models
• A piecewise modeling approach was used for ipilimumab: 
Methods
• KEYTRUDA ® (pembrolizumab) is a humanized, anti-programmed cell death-1 (PD-1) monoclonal IgG4 antibody. It has demonstrated clinical benefit in delaying disease progression, prolonging survival, 1 and improving quality of life of patients with advanced melanoma
• The objective of this study is to assess the cost-effectiveness of pembrolizumab compared with ipilimumab (IPI) in patients with advanced melanoma, previously untreated with IPI, from the perspective of a Canadian publicly funded healthcare system
AEs
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Postprogression Death
• A three-state partitioned survival model was developed to estimate the cost-effectiveness of pembrolizumab compared with IPI over a 20-year time horizon
• Movement between health states was determined by progression-free survival (PFS) and overall survival (OS) data using results from a randomized phase 3 study, KEYNOTE-006 (KN006), comparing pembrolizumab and ipilimumab 
Results
Sensitivity Analysis Result
• One-way sensitivity analyses showed that the input that has the most impact on the ICER is the proportion of patients in progression-free state at 2 years who were re-induced with a 1-year additional course of treatment. This proportion was varied between 0% and 100% from a base-case value of 50%
• The cost-effectiveness acceptability curve from the probabilistic sensitivity analysis showed an 85% probability that the ICER is below $60,000/QALY and a 99% probability that the ICER is below $75,000/QALY • Average number of vials per dose for pembrolizumab and ipilimumab was calculated based on the weight distribution of the patients in KN006
• Administration costs were estimated at $3.06/minute (2015 CAD) based on an economic evaluation of pancreatic cancer conducted by Tam et al. 6 The administration time is 30 and 90 minutes for pembrolizumab and ipilimumab, respectively
• Healthcare costs by health state were based on literature data 7
• The weighted average costs of AEs were included in the pre-progression state as one-off costs
• Treatment duration is modelled according to the KN006 protocol with a 2-year stopping rule, ie, patients stayed on treatment until disease progression, the onset of unacceptable side effects, or 2 years of therapy. Patients are eligible to receive up to 1 year of re-induction treatment if applicable 1
• The patients on ipilimumab were treated for a maximum of 4 cycles. The average was 3.3 cycles according to the trial data • Utility data were collected in the KN006 trial using the EQ-5D. Data were collected at Weeks 0, 3, 6, 12, 24, 36, the end of treatment, and at a 30-day safety follow-up visit
• Utility by health state was included in the model as the base case
• A sensitivity analysis included utility based on time to death, as in previous economic models for metastatic melanoma 5
• The impact of AEs was incorporated in the model via a weighted average of the disutilities applied to the pre-progression state 
